| Name | Title | Contact Details |
|---|---|---|
Hisao Kushi |
Co-Founder and Chief Legal Officer | Profile |
Mike Keefe |
Director, Legal | Profile |
Kristine Huggins |
Senior Employment Counsel | Profile |
Jasdeep Singh |
Associate Privacy Counsel | Profile |
David Frydman |
Merger and Acquisition and Corporate Counsel | Profile |
NYC Health + Hospitals is the nation`s largest public health care delivery system. We are an integrated network of hospitals, trauma centers, neighborhood health centers, nursing homes, and post-acute care centers. We are a home care agency and a health plan, MetroPlus. The health system provides essential services to more than 1.4 million New Yorkers every year in more than 70 patient care locations and in their homes. Our talented workforce of more than 40,000 represents the diversity of our city and the communities we serve. The excellence of our staff, and our continued mission to care for all without exception, make us unique and rightly positioned to provide equitable, high-quality, culturally responsive, and affordable health care in every New York City community. Our promise to New Yorkers: Empower every New Yorker – without exception – to live the healthiest life possible by providing equitable, high quality, culturally responsive, and affordable health care in every community.
Cybermedx Medical Systems is a Lebanon, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
t+ Medical Americas is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Shiseido Cosmetics America Ltd. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Shiseido Cosmetics America Ltd. is based in New York, NY. You can find more information on Shiseido Cosmetics America Ltd. at www.sca.shiseido.com
EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company`s pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert`s proven intravitreal drug delivery platform has been safely administered to thousands of patients` eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.